Trametinib for a BRAF G469A missense mutation in a neuroblastoma unveiled by liquid biopsy
Gauthier Toutain
Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM, Marseille, France
Search for more papers by this authorVictoria Min
Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM, Marseille, France
Search for more papers by this authorAngélique Rome
Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM, Marseille, France
Search for more papers by this authorCorresponding Author
Nicolas Andre
Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM, Marseille, France
Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM), CLIPP2, APHM, Marseille, France
SMARTc Unit, CRCM Inserm 1068-CNRS UMR 7258 Aix-Marseille University, Marseille, France
Correspondence
Nicolas Andre, Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM Blvd Jean Moulin, Marseille, France.
Email: [email protected]
Search for more papers by this authorGauthier Toutain
Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM, Marseille, France
Search for more papers by this authorVictoria Min
Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM, Marseille, France
Search for more papers by this authorAngélique Rome
Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM, Marseille, France
Search for more papers by this authorCorresponding Author
Nicolas Andre
Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM, Marseille, France
Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM), CLIPP2, APHM, Marseille, France
SMARTc Unit, CRCM Inserm 1068-CNRS UMR 7258 Aix-Marseille University, Marseille, France
Correspondence
Nicolas Andre, Department of Pediatric Oncology, La Timone University Hospital of Marseille, APHM Blvd Jean Moulin, Marseille, France.
Email: [email protected]
Search for more papers by this author
REFERENCES
- 1Dagogo-Jack I. Durable response to dabrafenib combined with trametinib in a patient with NSCLC harboring a BRAF G469A mutation. J Thorac Oncol. 2020; 15(10): e174-e176.
- 2Ladenstein R, Lambert B, Pötschger U, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018; 45: 292-305.
- 3Yaeger R, Corcoran RB. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019; 9(3): 329-341.
- 4Carter J, Tseng LH, Zheng G, et al. Non-p.V600E BRAF mutations are common using a more sensitive and broad detection tool. Am J Clin Pathol. 2015; 144(4): 620-628.
- 5Peeters SM, Muftuoglu Y, Na B, et al. Pediatric gliomas: molecular landscape and emerging targets. Neurosurg Clin N Am. 2021; 32: 181-190.
- 6Kinno T, Tsuta K, Shiraishi K, et al. Clinicopathological features of non-small cell lung carcinomas with BRAF mutations. Ann Oncol. 2014; 25: 138-142.
- 7Kronish A, De Nardo B, Kanach C, Lulla RR. Activating BRAF G469A missense mutation in a pediatric patient with high-grade glioma. J Neuropathol Exp Neurol. 2021; 80(12): 1141-1142.
- 8Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021; 18(5): 297-312.
- 9Berlanga P, Pierron G, Lacroix L, et al. The European MAPPYACTS trial: precision medicine program in pediatric and adolescent patients with recurrent malignancies. Cancer Discov. 2022; 12(5): 1266-1281.
